Antaros Medical methods at EASD on target engagement of the GIP-receptor and imaging of the heart and liver
September 21st, 2020
Today, the 56th annual meeting of the European Association for the study of diabetes (EASD) begins. There will be five full days focused on diabetes – a disease affecting over 400 million people world-wide (WHO). We are looking forward to engaging with the diabetes community and to share some new, exciting data from Antaros Medical.
Antaros Medical, in collaboration with Sanofi, are presenting data on the development of a Positron Emission Tomography (PET) ligand for the receptor of the incretin hormone Gastric Inhibitory Polypeptide (GIP). Targeting of the GIP receptor (GIPR) is one of several emerging strategies in anti-diabetic drug development. The presented data shows promise for a novel PET biomarker for safe, non-invasive, and quantitative assessment of GIPR target distribution and engagement.
Authors: O. Eriksson, I. Velikyan, T. Haack, M. Bossart, A. Evers, I. Laitinen, O. Plettenburg, G. Antoni, L. Johansson, S. Pierrou, M. Wagner
Time: 23 September 2020, 12:00 – 13:00
Abstract number: 578
Session: PS 45 Basic aspects of incretin-based therapies
In addition, Antaros Medical has contributed to the AstraZeneca poster presenting additional, exploratory data from the DAPACARD trial. The poster will be presented orally on the 23rd of September.
Authors: J. Oldgren, S. Laurila, A. Åkerblom, A. Latva-Rasku, E. Rebelos, H. Isackson1, M. Saarenhovi, O. Eriksson, K. Heurling, E. Johansson, U. Wilderäng, C. Karlsson, E. Ferrannini, J. Oscarsson, P. Nuutila;
Time: 23 September 2020, 15:15 – 15:30
Abstract number: 124
Session: OP 21 SGLT-2 inhibitors: at the heart of the matter
Back to all news